Illumina (ILMN) – Business Wire
-
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
-
GRAIL Presents New Data on Galleri® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting
-
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
-
Curative Insurance Company Adds GRAIL’s Galleri® Test to Member Benefits for Multi-Cancer Early Detection
-
GRAIL Partners With Professional Golfers Steve Stricker and Juli Inkster to Raise Awareness of Multi-Cancer Early Detection at Second Annual Galleri Classic PGA TOUR Champions Tournament
-
BeniComp to Offer GRAIL’s Multi-Cancer Early Detection Test for Employee Health Screening
-
Illumina Ventures Labs Launches in the US and the UK to Enable More Rapid Value-Creation for Start-Ups Advancing Human Health
-
Madryn Asset Management Reiterates Alternative Path to SomaLogic’s Value-Destructive Proposed Merger with Standard BioTools
-
Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company’s Proposed Merger with Standard BioTools
-
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
-
GRAIL To Initiate REACH Study To Evaluate Clinical Impact Of GalleriⓇ Multi-Cancer Early Detection (MCED) Test Among The Medicare Population
-
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
-
HCA Healthcare and Grail Collaborate to Advance Comprehensive Cancer Care With Multi-Cancer Early Detection Screening
-
MassMutual Launches Innovative Wellness Offerings That Help Policyowners Better Understand and Protect Their Health
-
Final Results From PATHFINDER Study of GRAIL’s Multi-Cancer Early Detection Blood Test Published in The Lancet
-
Point32Health and GRAIL Expand Pilot Access to Galleri® Multi-Cancer Early Detection Blood Test
-
Illumina Ventures Announces New Partner, Mara Aspinall, Has Joined Its Investment Team
-
Whitman-Walker Institute, Cancer Support Community and GRAIL Collaborate On Research Aimed at Advancing Health Equity in Cancer Screening and Care Through Multi-Cancer Early Detection
-
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
-
The Lancet Oncology Publishes Results from SYMPLIFY, The First Prospective Study of a Multi-Cancer Early Detection Test in a Symptomatic Patient Population
-
Illumina Ventures to Launch Illumina® Ventures Labs
-
New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing
-
GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting
-
GRAIL and University of Oxford to Present Results From First Prospective Study of Multi-Cancer Early Detection in a Symptomatic Patient Population at 2023 ASCO Annual Meeting
-
GRAIL to Present New Multi-Cancer Early Detection Data at the 2023 ASCO Annual Meeting
-
GRAIL Presents Positive Analytical Validation Data on its Methylation-Based Post-Diagnostic Cancer Research Solution at American Association for Cancer Research (AACR) Annual Meeting 2023
-
FirstHealth of the Carolinas to Offer GRAIL’s Galleri®, a Multi-Cancer Early Detection Blood Test
-
GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023
-
GRAIL Showcases Methylation Platform Performance Across Cancer Continuum With New Data at American Association for Cancer Research (AACR) Annual Meeting
-
Providence and GRAIL Expand Partnership to Increase Access to Galleri® Multi-Cancer Early Detection Screening
-
DNA Data Storage Alliance Announces Board Appointments
-
GRAIL Teams Up with Professional Golfers David Duval and Juli Inkster to Raise Awareness of Multi-Cancer Early Detection
-
Illumina Ventures Announces Strategic New Additions to its Investment Team
-
Grail Introduces State-of-the-Art Methylation-Based Solution to Accelerate Cancer Research in the Post-Diagnosis Setting
-
Point32Health and GRAIL Expand Galleri® Multi-Cancer Early Detection Blood Test Pilot to Harvard Pilgrim Health Care Members on the Maine Health Insurance Marketplace
-
GRAIL CCGA Discovery Results Published in Cancer Cell Reveal Methylation as Promising DNA Hallmark for Multi-Cancer Early Detection
-
Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research
-
GRAIL and Carrum Health Partner to Include Galleri® as Part of Comprehensive Cancer Care Offering to Employers
-
GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
-
CORRECTING and REPLACING GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
-
GRAIL to Present Final Multi-cancer Early Detection Data From the Interventional PATHFINDER Study at ESMO Congress 2022
-
Illumina Ventures Announces Expansion of its Europe Team
-
Grail and National Health Service (NHS) England Complete Enrollment of 140,000 Participants in Largest Study of Multi-Cancer Early Detection Test
-
Mercy Offers New GRAIL Blood Test to Detect 50+ Types of Cancer
-
Community Health Network and Grail Partner to Offer Galleri® Multi-Cancer Early Detection Test in Central Indiana
-
SNIA Announces DNA Data Storage Technology Affiliate
-
GRAIL and Fountain Health Insurance Partner to Provide Coverage of Galleri® Multi-cancer Early Detection Test
-
GRAIL and England’s National Health Service (NHS) Present Trial Design for Largest Study of Multi-Cancer Early Detection Test at ASCO Annual Meeting
-
GRAIL and Ochsner Health Launch New Initiatives to Improve Cancer Detection Rates in Louisiana
-
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer
Back to ILMN Stock Lookup
